These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38667024)

  • 1. Concomitant and Bismuth Quadruple Therapy for
    Losurdo G; Borraccino AV; Aloisio A; Russo F; Riezzo G; Galeano G; Pricci M; Girardi B; Celiberto F; Iannone A; Ierardi E; Di Leo A
    Antibiotics (Basel); 2024 Apr; 13(4):. PubMed ID: 38667024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metronidazole resistance on Helicobacter pylori eradication regimens.
    Losurdo G; Pricci M; De Bellis M; Celiberto F; Russo F; Riezzo G; D'attoma B; Iannone A; Rendina M; Ierardi E; Di Leo A
    J Dig Dis; 2022 Oct; 23(10):561-567. PubMed ID: 36321440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
    Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
    Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
    Romano M; Gravina AG; Nardone G; Federico A; Dallio M; Martorano M; Mucherino C; Romiti A; Avallone L; Granata L; Priadko K; Compare D; Tuccillo C; Romito MR; Sgambato D; Miranda A; Romano L; Loguercio C; Bazzoli F; Zagari RM
    Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
    Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
    Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single Capsule Bismuth Quadruple Therapy for Eradication of
    Gravina AG; Priadko K; Granata L; Facchiano A; Scidà G; Cerbone R; Ciamarra P; Romano M
    Front Pharmacol; 2021; 12():667584. PubMed ID: 33995097
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.
    Miehlke S; Frederking D; Günther T; Glocker E; Eisele B; Andresen V; Schröder S; Morgner A
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28833925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Macedo Silva V; Lima Capela T; Freitas M; Boal Carvalho P; Magalhães J; Cotter J
    Helicobacter; 2023 Jun; 28(3):e12962. PubMed ID: 36828647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for
    Cha B; Bang BW; Shin JB; Ko EJ; Ko W; Kwon KS; Shin YW; Suh YJ; Kim H
    Scand J Gastroenterol; 2021 Sep; 56(9):1017-1022. PubMed ID: 34369255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
    Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
    Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis.
    Guo B; Cao NW; Zhou HY; Chu XJ; Li BZ
    Microb Pathog; 2021 Mar; 152():104661. PubMed ID: 33249167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of insufficient doses of medications on
    Shi X; Wang C; Meng F; Ma S; Xu G; Liu T; Guo X; Li H; Qi X
    Postgrad Med; 2022 Sep; 134(7):668-674. PubMed ID: 35860966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line
    Losurdo G; Lacavalla I; Russo F; Riezzo G; Brescia IV; Rendina M; Ierardi E; Di Leo A
    Antibiotics (Basel); 2022 Jan; 11(1):. PubMed ID: 35052955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-line and rescue therapy for refractory
    de Moraes Andrade PV; Monteiro YM; Chehter EZ
    World J Gastroenterol; 2023 Jan; 29(2):390-409. PubMed ID: 36687120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
    Yozgat A; Kasapoğlu B; Demirci S; Coşkun Sökmen F
    Rev Esp Enferm Dig; 2021 Jul; 113(7):490-493. PubMed ID: 33233910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of
    Varga M; Drácz L; Kolbenheyer E; Varga F; Patai ÁV; Solymosi N; Patai Á
    Orv Hetil; 2019 Aug; 160(34):1340-1345. PubMed ID: 31423829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.